Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval

被引:1
|
作者
Miyamoto, Sho [1 ]
Kuroda, Yudai [2 ]
Kanno, Takayuki [1 ]
Ueno, Akira [1 ]
Shiwa-Sudo, Nozomi [1 ]
Iwata-Yoshikawa, Naoko [1 ]
Sakai, Yusuke [1 ]
Nagata, Noriyo [1 ]
Arashiro, Takeshi [1 ,3 ]
Ainai, Akira [1 ]
Moriyama, Saya [4 ]
Kishida, Noriko [5 ]
Watanabe, Shinji [5 ]
Nojima, Kiyoko [6 ]
Seki, Yohei [6 ]
Mizukami, Takuo [6 ]
Hasegawa, Hideki [5 ]
Ebihara, Hideki [7 ]
Fukushi, Shuetsu [7 ]
Takahashi, Yoshimasa [4 ]
Maeda, Ken [2 ]
Suzuki, Tadaki [1 ]
机构
[1] Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan
[2] Natl Inst Infect Dis, Dept Vet Sci, Tokyo 1628640, Japan
[3] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo 1628640, Japan
[4] Natl Inst Infect Dis, Res Ctr Drug & Vaccine Dev, Tokyo 1628640, Japan
[5] Natl Inst Infect Dis, Ctr Influenza & Resp Virus Res, Tokyo 2080011, Japan
[6] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo 2080011, Japan
[7] Natl Inst Infect Dis, Dept Virol 1, Tokyo 1628640, Japan
基金
日本学术振兴会;
关键词
Immune response; Immune system; Immunity; Virology;
D O I
10.1016/j.isci.2023.106694
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infec-tion, is challenging. To compare the impact of pre-Omicron to Omicron break-through infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2-4 months. The breadths of saturated cross -neutral-ization responses to Omicron lineages were comparable in pre-Omicron and Om-icron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
    Lin Cheng
    Shuo Song
    Qing Fan
    Senlin Shen
    Haiyan Wang
    Bing Zhou
    Xiangyang Ge
    Bin Ju
    Zheng Zhang
    Cell Discovery, 7
  • [12] Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
    Cheng, Lin
    Song, Shuo
    Fan, Qing
    Shen, Senlin
    Wang, Haiyan
    Zhou, Bing
    Ge, Xiangyang
    Ju, Bin
    Zhang, Zheng
    CELL DISCOVERY, 2021, 7 (01)
  • [13] Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
    Pavot, Vincent
    Berry, Catherine
    Kishko, Michael
    Anosova, Natalie G.
    Huang, Dean
    Tibbitts, Tim
    Raillard, Alice
    Gautheron, Sylviane
    Gutzeit, Cindy
    Koutsoukos, Marguerite
    Chicz, Roman M.
    Lecouturier, Valerie
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [14] Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
    Vincent Pavot
    Catherine Berry
    Michael Kishko
    Natalie G. Anosova
    Dean Huang
    Tim Tibbitts
    Alice Raillard
    Sylviane Gautheron
    Cindy Gutzeit
    Marguerite Koutsoukos
    Roman M. Chicz
    Valerie Lecouturier
    Nature Communications, 13
  • [15] Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies
    Lou, Yan
    Zhao, Wenxiang
    Wei, Haitao
    Chu, Min
    Chao, Ruihua
    Yao, Hangping
    Su, Junwei
    Li, Yanan
    Li, Xiulan
    Cao, Yu
    Feng, Yanyan
    Wang, Ping
    Xia, Yongyang
    Shang, Yushuan
    Li, Fengping
    Ge, Pingju
    Zhang, Xinglin
    Gao, Wenjing
    Song, Gaojie
    Du, Bing
    Liang, Tingbo
    Qiu, Yunqing
    Liu, Mingyao
    BIOTECHNOLOGY JOURNAL, 2021, 16 (11)
  • [16] Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
    Maria Diez, Jose
    Romero, Carolina
    Vergara-Alert, Julia
    Bello-Perez, Melissa
    Rodon, Jordi
    Manuel Honrubia, Jose
    Segales, Joaquim
    Sola, Isabel
    Enjuanes, Luis
    Gajardo, Rodrigo
    IMMUNOTHERAPY, 2020, 12 (17) : 1247 - 1255
  • [17] Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency
    Chiang, Chia-Jung
    Hsu, Wei-Lun
    Su, Mei-Tsz
    Ko, Wen-Chien
    Hsu, Keng-Fu
    Tsai, Pei-Yin
    VACCINES, 2024, 12 (02)
  • [18] Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes
    Yang Liu
    Jianying Liu
    Jing Zou
    Birte Kalveram
    Rafael R. G. Machado
    Ping Ren
    Sina Türeli
    Derek J. Smith
    Scott C. Weaver
    Xuping Xie
    Pei-Yong Shi
    Signal Transduction and Targeted Therapy, 7
  • [19] Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes
    Liu, Yang
    Liu, Jianying
    Zou, Jing
    Kalveram, Birte
    Machado, Rafael R. G.
    Ren, Ping
    Tureli, Sina
    Smith, Derek J.
    Weaver, Scott C.
    Xie, Xuping
    Shi, Pei-Yong
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [20] Antibody response over time after a third dose of SARS-CoV-2 vaccine
    Kim, Hyeon Hwa
    Sung, Heungsup
    Lee, Hye Kyung
    Hennighausen, Lothar
    Huh, Jin-Won
    RESPIROLOGY, 2023, 28 : 208 - 208